Holders — by stockHoldings — by fund
Davern Capital Partners, LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0002003147
$514.1M
disclosed book value
17
positions
13%
largest position share
Positions, as of 2026-09-30
top 17 of 17 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | BNTXBIONTECH SE | 682,148 | $67.1M | 13% |
| 2 | RPRXROYALTY PHARMA PLC | 974,412 | $56.9M | 11.1% |
| 3 | INSMINSMED INC | 496,047 | $56.6M | 11% |
| 4 | ROIVROIVANT SCIENCES LTD | 1.5M | $53.9M | 10.5% |
| 5 | IONSIONIS PHARMACEUTICALS INC | 1.1M | $48.5M | 9.4% |
| 6 | ARGXARGENX SE | 37,597 | $36.1M | 7% |
| 7 | REGNREGENERON PHARMACEUTICALS | 40,661 | $30.8M | 6% |
| 8 | NTRANATERA INC | 63,200 | $26.1M | 5.1% |
| 9 | ABVXABIVAX SA | 219,183 | $21.7M | 4.2% |
| 10 | VERAVERA THERAPEUTICS INC | 628,274 | $20.3M | 3.9% |
| 11 | MLYSMINERALYS THERAPEUTICS INC | 695,152 | $17.5M | 3.4% |
| 12 | LEGNLEGEND BIOTECH CORP | 828,880 | $16.5M | 3.2% |
| 13 | ARWRARROWHEAD PHARMACEUTICALS IN | 229,300 | $15.0M | 2.9% |
| 14 | LLYELI LILLY & CO | 12,600 | $14.6M | 2.8% |
| 15 | GENBGENERATE BIOMEDICINES INC | 824,679 | $12.4M | 2.4% |
| 16 | VRDNVIRIDIAN THERAPEUTICS INC | 560,710 | $11.5M | 2.2% |
| 17 | AVTXAVALO THERAPEUTICS INC | 564,441 | $8.7M | 1.7% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.